Welcome to LookChem.com Sign In|Join Free
  • or
C23H29N5O6S is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

1421338-19-3

Post Buying Request

1421338-19-3 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

1421338-19-3 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 1421338-19-3 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,4,2,1,3,3 and 8 respectively; the second part has 2 digits, 1 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 1421338-19:
(9*1)+(8*4)+(7*2)+(6*1)+(5*3)+(4*3)+(3*8)+(2*1)+(1*9)=123
123 % 10 = 3
So 1421338-19-3 is a valid CAS Registry Number.

1421338-19-3Relevant academic research and scientific papers

Structure activity optimization of 6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyrazines as Jak1 kinase inhibitors

Friedman, Michael,Frank, Kristine E.,Aguirre, Ana,Argiriadi, Maria A.,Davis, Heather,Edmunds, Jeremy J.,George, Dawn M.,George, Jonathan S.,Goedken, Eric,Fiamengo, Bryan,Hyland, Deborah,Li, Bin,Murtaza, Anwar,Morytko, Michael,Somal, Gagandeep,Stewart, Kent,Tarcsa, Edit,Van Epps, Stacy,Voss, Jeffrey,Wang, Lu,Woller, Kevin,Wishart, Neil

, p. 4399 - 4404 (2015/10/12)

Previous work investigating tricyclic pyrrolopyrazines as kinase cores led to the discovery that 1-cyclohexyl-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyrazine (12) had Jak inhibitory activity. Herein we describe our initial efforts to develop orally bioavailable analogs of 12 with improved selectivity of Jak1 over Jak2.

Design and synthesis of tricyclic cores for kinase inhibition

Van Epps, Stacy,Fiamengo, Bryan,Edmunds, Jeremy,Ericsson, Anna,Frank, Kristine,Friedman, Michael,George, Dawn,George, Jonathan,Goedken, Eric,Kotecki, Brian,Martinez, Gloria,Merta, Philip,Morytko, Michael,Shekhar, Shashank,Skinner, Barbara,Stewart, Kent,Voss, Jeffrey,Wallace, Grier,Wang, Lu,Wishart, Neil

, p. 693 - 698 (2013/03/13)

Interest in therapeutic kinase inhibitors continues to grow beyond success in oncology. To date, ATP-mimetic kinase inhibitors have focused primarily on monocyclic and bicyclic heterocyclic cores. We sought to expand on the repertoire of potential cores for kinase inhibition by exploring tricyclic variants of classical bicyclic hinge binding motifs such as pyrrolopyridine and pyrrolopyrazine. Herein we describe the syntheses of eight alternative tricyclic cores as well as in vitro screening results for representative kinases of potential therapeutic interest.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 1421338-19-3